All In Biotech

Drug Trial Radar · NCT02956772

Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

Last checked: Nov 20, 2026Latest source record: Feb 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

190

Planned (sponsor's estimate)

Start

Nov 2016

Primary completion

Nov 2019

Study completion Nov 2020

Sponsor

Lead sponsor
Hunan Provincial People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicentre, randomized, open-label, parallel-group, active controlled study.

Conditions

  • Primary Hepatocellular Carcinoma

Interventions

  • TACEDrug

    After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.

  • Arsenic trioxideDrug

    Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: 2-year

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Guizhou Cancer Hospital

    Guiyang, Guizhou, China

  • Guizhou Province Tumor Hospital

    Guiyang, Guizhou, China

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Xinjiang Medical University Cancer Hospital

    Ürümqi, Xinjiang, China

  • The Tumor Hospital of Yunnan Province

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.